Clinical Trials Logo

Tremor clinical trials

View clinical trials related to Tremor.

Filter by:

NCT ID: NCT04071847 Recruiting - Parkinson Disease Clinical Trials

Abbott DBS Post-Market Study of Outcomes for Indications Over Time

ADROIT
Start date: November 26, 2019
Phase:
Study type: Observational

The purpose of this international study is to evaluate long-term safety and effectiveness of Abbott deep brain stimulation (DBS) systems for all indications, including Parkinson's disease, essential tremor or other disabling tremor and dystonia.

NCT ID: NCT04032470 Recruiting - Essential Tremor Clinical Trials

Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (ET)

Start date: October 23, 2019
Phase:
Study type: Observational [Patient Registry]

To compile characteristics of real-world outcomes for Boston Scientific Corporation's commercially approved Deep Brain Stimulation (DBS) Systems, when used according to the applicable Directions for Use, for the treatment of Essential Tremor.

NCT ID: NCT03992625 Recruiting - Parkinson Disease Clinical Trials

Clinical Outcomes for Deep Brain Stimulation

Start date: January 3, 2011
Phase:
Study type: Observational

The object of this study is to longitudinally collect clinical outcomes of patients receiving deep brain stimulation for movement disorders with the objective of making retrospective comparisons and tracking of risks, benefits, and complications.

NCT ID: NCT03952117 Recruiting - Essential Tremor Clinical Trials

Transcranial Direct Current Stimulation of the Motor Cortex in Essential Tremor

Start date: July 19, 2019
Phase: N/A
Study type: Interventional

The current research is aimed at using Transcranial Direct Current Stimulation (tDCS) as complementary therapeutic tool in the treatment of essential tremor. Patients will be randomized into two groups (tDCS-cathode vs. tDCS-sham) according to detailed protocol. Main outcome will be measured by the change in tremor amplitude using an accelerometer pre and post cathodal tDCS of the motor cortex. A total of 40 patients ought to be enrolled as specified in methodology. Secondary outcomes will assess TRG essential tremor rating assessment scale (TETRAS) as well as clinical monitoring.

NCT ID: NCT03832712 Recruiting - Essential Tremor Clinical Trials

The Swedish Essential Tremor (SWEET) Trial

SWEET
Start date: June 30, 2018
Phase: N/A
Study type: Interventional

To evaluate the effect of deep brain stimulation (DBS) vs best medical treatment in essential tremor (ET) in a randomized, single-blinded controlled trial.

NCT ID: NCT03811405 Recruiting - Parkinson Disease Clinical Trials

Physiology, Imaging and Modeling of Essential Tremor

Start date: April 1, 2021
Phase: N/A
Study type: Interventional

This project aims to investigate novel ways to deliver brain stimulation to Essential Tremor (ET) patients by introducing software changes to their existing devices. The study team aims to investigate safety and efficacy of these new stimulation parameters in patients with ET.

NCT ID: NCT03795935 Recruiting - Essential Tremor Clinical Trials

Relief From Side Effects: Clinical Use of Electrodes With Direction

RESCUED
Start date: September 17, 2018
Phase: N/A
Study type: Interventional

Deep Brain Stimulation (DBS) uses electrical pulses sent through a lead (insulated wire) to help stop unwanted symptoms in a variety of brain diseases, including the tremor seen in patients with Essential Tremor (ET). The current standard lead allows this stimulation to spread out uniformly in all directions. As these diseases progress, however, the amount of electrical stimulation required to stop the symptom usually increases. This may become problematic because the increased electrical stimulation required for advanced symptoms may spread outside the desired targeted area, and effect other parts of the brain and causing unwanted side effects. A new type of DBS lead has been developed which can steer, or focus, the electrical stimulation in a given direction toward the desired target area and away from areas that would cause side effects. We would like to quantify the benefit seen in patients who have been switched from the traditional lead to this new directional lead.

NCT ID: NCT03530033 Recruiting - Thyroid Cancer Clinical Trials

Lidocaine Reduces Muscle Tremor is Beneficial for Intraoperative Recurrent Laryngeal Nerve Monitoring

Start date: May 1, 2018
Phase: N/A
Study type: Interventional

In recent years, the application of intraoperative recurrent laryngeal nerve monitoring in thyroid surgery has greatly reduced the complications of recurrent laryngeal nerve injury. The use of intraoperative neurological monitoring requires the reduction of the dose of neuromuscular blockade, which often leads to muscle tremors during the application of electrical energy, which affects the fine separation around the muscles. This study explored the effect of local application of lidocaine on reducing muscle tremor during surgery and its optimal dose.

NCT ID: NCT03465761 Recruiting - Essential Tremor Clinical Trials

Staged Bilateral Exablate Treatment of Medication Refractory Essential Tremor

Start date: January 3, 2019
Phase: N/A
Study type: Interventional

The objective of this prospective, multi-site, single-arm, open-label study is to capture the safety and efficacy (outcome) of bilateral staged Exablate treatment in subjects with bilateral medication-refractory essential tremor (ET). The staged second procedure will be performed at least 9 months after the first side. The benefit of real-time feedback will allow the physician to maximize benefit without jeopardizing safety. This study is designed as a prospective, open-label, single arm, multi-site study design.

NCT ID: NCT03350139 Recruiting - Clinical trials for Severe Disabling Tremor

Evaluation of the Predictors of Clinical and Radiological Response to Gamma-Knife Radiosurgery in the Treatment of Intermediate Ventral Nucleus of the Thalamus (VIM) Thalamotomy Tremor.

GARP
Start date: October 23, 2017
Phase: N/A
Study type: Observational

Gamma-Knife radiosurgery of the VIM for patients presenting with severe drug-resistant tremor is now current practice as an alternative to Deep Brain Stimulation (DBS) of the VIM. Now, around 100 patients are treated annually in our unit (essential tremor or Parkinson tremor). Clinical and radiological follow-up is demonstrating that 80% of these patients are presenting with a homogenous response complete or subtotal, the disappearance of the tremor mean delay of 6 months after radiosurgery. In neuroradiological responses on the MRI, is appearing roughly at the same time local contrast enhancement surrounding highty to signal no associated with clinical side effects. In 15 to 20% of the patients, the clinical effets is not obtained and in the vast majority no MRI response or minimal MRI response is observed on images suggesting that these failures are related to specific resistance to radiosurgery of this subgroup. In roughly 5% of the patients, at the contrary, hyper response is observe on the MRI rating clinically with side effects (hemiparesis or proprioceptive ataxia or dysarthria, hands problems….). The adverse effects are generally reversible either in whole or in part with the resorption of the perilesionnel oedema. It would be extremely helpfull to be able to identify in advance these 2 groups of hyper and hypo respondeurs. The capacity to identify in advance these patients at risk to hypo or hyper response would allow us to either contre-indicate radiosurgery or modify radiosurgery technicaly at the time of dose planing. Sequently, these predictions would allow us to tailor individually mission management and information leading to improvment of the efficacy and tolerance of this kind of intervention. The parameters suspected to be likely to influence the response are : - genetics - co-morbidities (diabetis, vascular…) - Main aspect of the brain (severe atrophy, vascular, micro-infacts…) - Chronobiological (timing during the day of the radiosurgical procedure) - Associated medication (potential radioprotector or radiosensitizer effect of some drugs) - Radiobiological (dose rate…) The goal of this study is to collect all of these informations out of genetical one in the cohort of 700 patients having benefited ou will benefit from radiosurgery in the situation for essential tremor and parkinson disease. It will be test the predictive value of these parameters and the capacity to predict hyper or hypo response. The work on the genetic material will take place in the second stage in the frame of a new different resarch project.